Clinical Trials Browser

Phase 1/2 × milatuzumab × Other hematologic neoplasm × Clear all

NCT01585688 2021-10-08

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Phase 1/2 Terminated

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00868478 2010-06-02

The Humanized Monoclonal Antibody Milatuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Unknown

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell